Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for bendroflumethiazide

  1. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 25 June 2025

  2. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 17 December 2025

  3. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development [GID-TA11662] Expected publication date: 17 December 2025

  4. Preventive treatment following shockwave lithotripsy:- What is the clinical and cost effectiveness of empirical potassium citrate or bendroflumethiazide as preventive treatment for people with small residual fragments following shockwave lithotripsy for renal and ureteric stones?

    clinical and cost effectiveness of empirical potassium citrate or bendroflumethiazide as preventive treatment for people with small...

  5. Hypertension in adults: diagnosis and management (NG136)

    This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

  6. Renal and ureteric stones: assessment and management (NG118)

    This guideline covers assessing and managing renal and ureteric stones. It aims to improve the detection, clearance and prevention of stones, so reducing pain and anxiety, and improving quality of life.

  7. Research recommendations

    clinical and cost effectiveness of empirical potassium citrate or bendroflumethiazide as preventive treatment for people with small...